Cathy Anne Pinto (Cathy A Pinto)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 6

Top Venues

The patient

Patient preference and adherence

Acta oncologica (Stockholm, Sweden)

Immunotherapy

Merck and Co Inc

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Merck and Co Inc Feb 15 2003

United States

Sr. Principal Scientist :: Pharmacoepidemiology

Publications

Cathy Anne Pinto, Tommi Tervonen, Aura Cecilia Jimenez-Moreno, Bennett Levitan, Montse Soriano Gabarró, Cynthia J Girman, Josephine M Norquist, A Brett Hauber
Current Practices and Challenges When Submitting Patient Experience Data for Regulatory Decisions by the US Food and Drug Administration: An Industry Survey. The patient (2023)
Frede Donskov, Cathy Anne Pinto, Raluca Predoiu, Claire Fox, Jeanette Baehr Georgsen, Katrine Skaarup, Mehmet Burcu, Rodolfo Perini, Torben Steiniche
Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma. Acta oncologica (Stockholm, Sweden) 61 (10) (2022)
Cathy Anne Pinto, Xinyue Liu, Xiaoyun Nicole Li, Emilie Scherrer, Mizuho Kalabis
Treatment and overall survival among anti-PD-1-exposed advanced melanoma patients with evidence of disease progression. Immunotherapy (2021)
Selena Russo, Dario Monzani, Cathy Anne Pinto, Laura Vergani, Giulia Marton, Marie Falahee, Gwenda Simons, Chiara Whichello, Ulrik Kihlbom, Gabriella Pravettoni
Taking into Account Patient Preferences: A Consensus Study on the Assessment of Psychological Dimensions Within Patient Preference Studies. Patient preference and adherence 15 (2021)
Cathy Anne Pinto, Gin Nie Chua, John F P Bridges, Ella Brookes, Johanna Hyacinthe, Tommi Tervonen
Comparing Patient Preferences for Antithrombotic Treatment During the Acute and Chronic Phases of Myocardial Infarction: A Discrete-Choice Experiment. The patient (2021)
Cathy Anne Pinto, Tommi Tervonen, Kevin Marsh, Dimitra Lambrelli, Anna Schultze, Andrew Tershakovec, Johanna Hyacinthe, Thibaud Prawitz, Tarek A Hammad
Personalized benefit-risk assessments combining clinical trial and real-world data provide further insights into which patients may benefit most from therapy: Demonstration for a new oral antiplatelet therapy. Pharmacoepidemiology and drug safety 28 (4) (2019)

Cathy Anne Pinto.css-eqlu8i{font-size:small;padding-left:4px;} (Cathy A Pinto)

Publication Activity (10 Years)

Top Topics

Top Venues

Cathy Anne Pinto (Cathy A Pinto)